Trial summary: | This study investigates whether administering chemotherapy before surgery, known as neoadjuvant chemotherapy, can improve outcomes for individuals with resectable pancreatic cancer. |
Status: | OPEN - Recruiting |
Trial identifier: | ACTRN12624000005550p |
Sponsor: | Seoul National University |
Phase: | III |
Diagnosis: | Resectable pancreatic ductal adenocarcinoma |
Line of therapy: | First-line |
Treatment: | Surgery with mFOLFIRINOX chemotherapy |
-
Key inclusion criteria
- Age: 18 – 80 years
- Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0 – 2
- Pancreatic ductal adenocarcinoma diagnosed by histological examination (histologic or cytopathological)
- Patients evaluated for resectable pancreatic cancer on preoperative imaging as follows (NCCN guidelines for pancreatic adenocarcinoma version 2.2021):
- There is no arterial tumour contact (celiac artery, superior mesenteric artery, or common hepatic artery).
- There is no tumour contact with the superior mesenteric vein or portal vein or ≤ 180° contact without vein contour irregularity.
- No distant metastases on preoperative imaging
- Patients with adequate organ function:
- Bone marrow function: WBC ≥ 3,000/mm3 or absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet ≥ 100 K/mm3
- Liver function: bilirubin ≤ 3 × the upper normal limit (≤ 5.0 mg/dL), AST/ALT ≤ 5 the upper normal limit (< 200 IU/L)
- Renal function: Creatinine clearance (Cr) ≥ 60 mL/min or Cr < 1.5 x upper normal limit
- Persons physically capable of undergoing surgery
- Those who consented to the clinical trial
-
Key exclusion criteria
- Those evaluated as borderline resectable or locally advanced pancreatic cancer in preoperative imaging examination
- Patients with a history of previous pancreatic surgery
- Patients with a history of previous chemotherapy or radiation therapy for pancreatic cancer
- Patients with distant metastases or recurrent pancreatic cancer
- Pancreatic body or tail cancer requiring combined resection of adjacent organs (stomach or kidney), except for the adrenal gland
- Patients within five years of diagnosis of other organ malignancies (with the exception of adequately treated non-melanoma skin cancer and carcinoma in situ without evidence of disease)
- Pregnant and lactating women
- Serious concomitant systemic disorders that would compromise the safety of the patient or patient's ability to complete the study at the discretion of the investigator
NeoFOL-R
Locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).
Epworth PI: Mr Julian Choi
Jreissati Pancreatic Centre at Epworth
Access this Clinical Trial
Healthcare professionals
General enquiries
Please contact us for more information on 03 9426 8880 or email [email protected]